Evaluation of the Long-Term Survival in Non-Metastatic Young Breast Cancer Patients in South of Iran

Behnam Kadkhodaei1, Ahmad Mosalaei2, Shapour Omidvari3,4, Mansour Ansari3,4, Mohammad Mohammadianpanah1,5, Niloofar Ahmadloo1, Hamid Nasrollahi1, Seyed Hassan Hamedi1, Mehdi Shariat1, Mozhdeh Zamani1,6

1. Dept. of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
2. Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3. Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4. Autophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

ABSTRACT

Background & Objective: The lack of breast cancer screening in young women leads to late disease diagnosis and worse outcomes in this age group. This study was designed to evaluate clinicopathological features and long-term outcomes of young breast cancer women in south of Iran.

Materials & Methods: This is a retrospective study of breast cancer patients who were pathologically diagnosed during 2005 to 2017. Data from 284 breast cancer patients aged 40 years or younger were included in this study. Demographic, clinicopathological properties as well as treatment modalities including type of surgery, adjuvant radiotherapy, and adjuvant or neoadjuvant chemotherapy were recorded and analyzed.

Results: Median age of the patients was 36 (range 23–40) years. After a median follow-up of 68 months, 21 patients had died due to the disease, 59 patients were alive with the disease, and 204 patients were alive without the disease. The univariate COX regression demonstrated that the disease-free survival (DFS) was significantly low in patients who had undergone breast conservation surgery (BCS) and also patients with higher stages, estrogen/progesterone-negative and human epidermal growth factor receptor 2-positive (ER-/PR-/HER2+) status. Low overall survival (OS) was also significantly associated with stage. According to multivariate Cox regression, BCS, stages II, III and also young age were independent predictive factors for low DFS.

Conclusion: Given the aggressive features and worse outcome of young breast cancer patients, treatment remains tough and screening seems to be required at young age. Further studies are required to find best management and therapeutic protocols for these patients.

Keywords: Breast cancer, Young age, Overall survival, Disease-free survival

Introduction

Breast cancer is known as the most frequent cancer affecting women around the world particularly in developed countries (1,2). Although this cancer occurs more frequently in women over 50 years of age, recent increasing incidence rates of breast cancer in young women under 40 years of age attract particular attention (3). It has been estimated that about 7% and 4% of all diagnosed breast cancers are in women < 40 years and < 35 years, respectively (4). Due to low incidence in young age, breast cancer screening programs are not performed for these women, which unfortunately leads to late diagnosis of disease in the symptomatic phase with advanced stage (3,5). A large population-based study described some risk factors for breast cancer in premenopausal women including combination of high caloric intake, obesity, sedentary lifestyle, and high alcohol and red meat consumption. Body mass index (BMI) is positively associated with high breast cancer risk in post-menopausal women (6,7). The incidence of breast cancer during pregnancy (BCP) has increased within the last few decades. The postponing of childbearing and high maternal age in developed and also several developing countries lead to the increase of the BCP cases (8,9). Previous estimations show that about 10-20% of breast cancers in 30-year-olds or younger women are recognized either within pregnancy or during the first year after delivery (10,11). Since young patients are at higher risk due to their age, adjuvant therapies should be
considered within treatment management. However, there are several long-term side effects like early menopause induction, fertility defects, reduction of bone mineral density and development of secondary malignancy due to chemotherapy and radiotherapy (12-14). Although breast cancer is relatively uncommon in young women, it is considered a remarkable clinical concern due to its worse clinical outcome. The goal of this study was to evaluate the clinicopathological characteristics and long-term clinical outcomes of young breast cancer women in Shiraz, Iran.

Materials and Methods

Study design and data collection
This study was designed as a retrospective study of breast cancer patients who were pathologically diagnosed during 2005 to 2017 and treated at the Radiotherapy and Oncology Center of Namazi Hospital in Shiraz, as a referral center in the south of Iran. Finally, data from 284 breast cancer patients who were 40 years old or younger were included in this study. The baseline demographic and clinicopathological features including age, hormone receptors status (Estrogen Receptor (ER), Progesterone Receptor (PR) and the human epidermal growth factor receptor 2 (HER2) receptor), histological type, stage, T and N stages, grade, operation type, relapse, the presence of lymphovascular invasion (LVI), chemotherapy timing, and adjuvant radiotherapy were recorded and analyzed.

Table 1. Baseline characteristics of young breast cancer patients

| Characteristics                  | Number of Patients (%) |
|----------------------------------|------------------------|
| **Categorized age in years**     |                        |
| 20 to 25                         | 16(5.6)                |
| 26 to 30                         | 30 (10.6)              |
| 31 to 35                         | 85(29.9)               |
| 36 to 40                         | 153(53.9)              |
| **Hormone Receptor Status**      |                        |
| ER+,PR+,HER2-                    | 166(58.5)              |
| ER-,PR-,HER2+                    | 26(9.2)                |
| ER+,PR+,HER2+                    | 39(13.7)               |
| ER-,PR-,HER2-                    | 49(17.3)               |
| Missing/unknown                  | 4(1.4)                 |
| **Histological type**            |                        |
| Ductal                           | 270(95.1)              |
| Lobular                          | 6(2.1)                 |
| Medullary                        | 7(2.5)                 |
| Papillary                        | 1(0.4)                 |
| **Stage**                        |                        |
| I                                | 59 (20.8)              |
| II                               | 160 (56.3)             |

The minimum and maximum follow-up of patients were 36 and 156 months for patients who were pathologically diagnosed in 2017 and 2005, respectively.

Statistical analysis
SPSS version 20 (SPSS Inc., Chicago, IL, USA) was applied for data analysis. Disease-free survival (DFS) and overall survival (OS) were analyzed using the Kaplan-Meier (KM) estimation method. Both univariate and multivariate Cox regression analyses were applied in order to identify the independent predictive variables for survival. The $P$ values less than 0.05 were considered to be statistically significant.

Ethical Considerations
Ethical approval for the study was obtained from the Institutional Ethics Committee of Shiraz University of Medical Sciences (SUMS) according to the Helsinki declaration (Ethic code: IR.SUMS.MED.REC.1397.232). All patients were informed about the aim of the study and asked to complete the informed consent form.

Results
On days 11, 17 and 24, the animals receiving MPH tra-
All patients were categorized into several age groups including 20 - 25 years, 26 - 30 years, 31 - 35 years, and 36 - 40 years. After a median follow up of 68 (range, 36 - 156) months, 21 patients had died due to the disease. Most of the patients were in the age group of 36-40 years (53.9%) and identified with ductal histological type (95.1%), stage II (56.3%), T2 stage (61.6%), N1 stage (42.6%) and grade II (45.8%). The positive expression of the ER and PR along with negative expression of the HER2 receptor (ER+/PR+/HER2-) was observed in most of the patients (58.5%). Lymphovascular invasion (LVI) was observed in almost half of the patients (50.7%). Totally, 75% of the breast cancer patients were treated with breast conservative surgery (BCS). Among all 80 patients who developed relapse, 9 (3.2%) and 71 (25%) had local and distant recurrence, respectively. Most of the patients received postoperative adjuvant chemotherapy (78.2%) and postoperative adjuvant radiotherapy (98.6%). Evaluation of the potential association between baseline and clinicopathological features and DFS or OS was made using univariate Cox regression (Table 2).
Table 2. Univariate Cox Regression Analysis of Disease-Free Survival and Overall Survival

| Parameters         | DFS          |          |          | OS          |          |
|--------------------|--------------|----------|----------|-------------|----------|
|                    | HR  | 95% CI   | P value | HR  | 95% CI   | P value |
| Categorized Age in Years |     |          |         |              |          |
| 20 to 25           | 0.938 | 0.324-2.709 | 0.905   | 0.776   | 0.070-8.593 | 0.836   |
| 26 to 30           | 0.853 | 0.328-2.213 | 0.743   | 0.419   | 0.043-4.048 | 0.452   |
| 31 to 35           | 0.580 | 0.227-1.481 | 0.255   | 1.049   | 0.17-8.003  | 0.964   |
| 36 to 40           | 1.000 | 0.000-3.160 | 1.000   | 0.000   | 0.000-1.000 | 1.000   |
| Stage              | 0.009 |          | 0.011   |          |          |
| I                  | 1.000 |          | 1.000   |          |          |
| II                 | 2.511 | 1.133-5.565 | 0.023   | 1.179   | 0.245-5.682 | 0.837   |
| III                | 3.508 | 1.522-8.081 | 0.003   | 3.959   | 0.882-17.759 | 0.072   |
| T Stage            | 0.619 |          | 0.129   |          |          |
| T1                 | 1.000 |          | 1.000   |          |          |
| T2                 | 0.997 | 0.578-1.720 | 0.990   | 1.207   | 0.326-4.460 | 0.778   |
| T3                 | 1.017 | 0.500-2.070 | 0.962   | 2.857   | 0.753-10.837 | 0.123   |
| T4                 | 2.517 | 0.583-10.865 | 0.216   | 5.158   | 0.527-50.492 | 0.159   |
| N Stage            | 0.004 |          | 0.046   |          |          |
| N0                 | 1.000 |          | 1.000   |          |          |
| N1                 | 2.301 | 1.013-5.226 | 0.047   | 2.422   | 0.512-11.464 | 0.265   |
| N2                 | 2.713 | 1.142-6.445 | 0.024   | 0.805   | 0.133-4.852 | 0.813   |
| N3                 | 4.215 | 1.799-9.879 | 0.001   | 3.917   | 0.831-18.470 | 0.084   |
| Grade              | 0.894 |          |         |          |          |
| I                  | 1.000 |          | 1.000   |          |          |
| II                 | 1.009 | 0.626-1.626 | 0.970   | -       | -        | -       |
| III                | 1.170 | 0.598-2.291 | 0.646   | -       | -        | -       |
| Operation Type     | 0.019 |          | 0.832   |          |          |
| Mastectomy         | 1.000 |          | 1.000   |          |          |
| Breast Conservation (BCS) | 1.930 | 1.103-3.376 | 0.903   | 0.349-2.333 |          |
| LVI                | 0.622 |          | 0.674   |          |          |
| Negative           | 1.000 |          | 1.000   |          |          |
| Positive           | 0.895 | 0.577-1.390 | 1.201   | 0.510-2.830 |          |
| Hormone receptor Status | 0.083 |          | 0.906   |          |          |
| ER+,PR+,HER2-      | 1.000 |          | 1.000   |          |          |
| ER-,PR-,HER2+      | 2.272 | 1.193-4.326 | 0.013   | 1.481   | 0.330-6.656 | 0.608   |
| ER+,PR+,HER2+      | 1.606 | 0.859-2.999 | 0.138   | 1.389   | 0.391-4.939 | 0.612   |
| ER-,PR-,HER2-      | 1.019 | 0.543-1.914 | 0.953   | 0.802   | 0.226-2.848 | 0.733   |

DFS: Disease Free Survival, OS: Overall survival, HR: Hazard Ratio, CI: Confidence interval, LVI: Lymphovascular Invasion, ER: Estrogen receptor, PR: Progesterone receptor
Low DFS was associated with stage II and stage III, as well as N1, N2, N3, Breast Conservation surgery, and ER-/PR-/HER2+ (p<0.05) (Figure 1).

Figure 1. Kaplan-Meier survival curves for young breast cancer patients categorized based on operation type (A), stage (B), and N stage (C) with P<0.05. BCS: breast-conserving surgery

Low OS was also associated with stage III and N3 stage (p<0.05). Determination of the variable interactions which could affect survival was performed using multivariate Cox regression analysis. According to this step, independent DFS predictive factors were BCS, stage II and stage III and also young age (p <0.05) (Table 3).

Table 3. Multivariate Cox Regression Analysis of Disease-Free Survival and Overall Survival

| Parameters                        | DFS                  |
|-----------------------------------|----------------------|
|                                   |         HR    | 95% CI     | P value |
| **Operation type**                |                       |            |         |
| Mastectomy                        | 1         |            | 0.002   |
| Breast Conservation               | 2.567     | 1.425-4.624|         |
| **Stage**                         |                       |            |         |
| I                                 | 1         |            | 0.001   |
| II                                | 2.703     | 1.161-6.291| 0.021   |
| III                               | 4.868     | 0.050-11.56| 0.000   |
| **Categorized age in year**       |                       |            | 0.055   |
| 20 to 25                          | 1         |            |         |
| 26 to 30                          | 0.744     | 0.250-2.214| 0.595   |
| 31 to 35                          | 0.577     | 0.211-1.579| 0.285   |
Discussion

Despite the low incidence of breast cancer in young women, it is considered as a clinically significant concern owing to its worse clinical outcome. Therefore, raising the knowledge about breast cancer in young women can contribute to improved patient management. According to the growing evidence, compared to older patients, young breast cancer patients face with more aggressive pathological features including the presence of LVI, grade 3 histology, absence of estrogen receptor (ER), and overexpression of the human epidermal growth factor receptor-2 (HER-2) oncogene (3, 4, 15). Therefore, young patients aged less than 40 years are found with the higher risk of loco-regional recurrence, distant metastasis, and death compared to older patients (16). Based on previous reports, a 5% rise in death risk was observed in patients aged < 35 years for every one-year reduction in age, whereas no such changes were observed in patients aged 35-50 years. Therefore, sharp increase of the death risk was reported in patients younger than 35 years (17). In consistence with previous reports our retrospective study described that low DFS was associated with higher stages (II, III, N1, N2 and N3) and ER-/PR-/HER2+ status. Low OS was also significantly associated with higher stages (II, N3).

Although there are similar managing principles for invasive breast cancer in both young and older women special considerations should be given to management and therapeutic protocols. Young patients are at higher risk of emotional and psychosocial problems and need proper support from medical and psychosocial multidisciplinary teams (18, 19). Regarding the quality of life, breast-conserving surgery is more favorable for most young women compared to mastectomy. However, in the young patients (aged <35 years) the risk of local recurrence after breast-conserving surgery is nine times higher than older patients (aged >60 years). Although we found a significant association between low DFS and breast conservation surgery (BCS), similar to previous reports (18), no negative impact on the OS was observed after conservative surgery in young women (aged ≤40 years). Our results confirm previous reports that age is an important factor affecting the breast cancer prognosis and there is a significant association between young age and low DFS. The limitation of our study is that the type of chemotherapy was not included in the analysis.

Conclusion

Taken together, our findings confirm that despite lower incidence of breast cancer in young women, worse outcomes in this age group make it a major concern. Therefore, it seems that screening is important to be considered in young women in order to diagnose breast cancer early in this high-risk age group and decrease the risk of mortality. Further studies may be helpful to find best management strategies for young breast cancer patients.

Acknowledgments

This work was supported by a grant from the Research Council of Shiraz University of Medical Sciences, Shiraz, Iran.

Conflict of Interest

The authors declare that they have no competing interests.

References

1. Merlo DF, Ceppi M, Filiberti R, et al. Breast cancer incidence trends in European women aged 20-39 years at diagnosis. Breast Cancer Res Treat. 2012;134(1):363-70. [DOI:10.1007/s10549-012-2031-7] [PMID]

2. Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020; 20:417-436. [DOI:10.1038/s41568-020-0266-x] [PMID]

3. Schaffar R, Bouchardy C, Chappuis PO, Bodmer A, Benhamou S, Rapiti E. A population-based cohort of young women diagnosed with breast cancer in Geneva, Switzerland. PloS one. 2019;14(9). e0222136. [PMCID]

4. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PloS one. 2009;4(11). e7695. [PMID]

5. Fabiano V, Mando P, Rizzo M, et al. Breast cancer in young women presents with more aggressive pathologic characteristics: Retrospective Analysis From an Argentine National Database. JCO Glob Oncol. 2020;6: 639-646. [DOI:10.1200/JGO.19.00228] [PMID]

6. Silvera SAN, Jain M, Howe GR, Miller AB, Rohan TE. Energy balance and breast cancer risk:
a prospective cohort study. Breast Cancer Res Treat 2006;97(1):97-106. [DOI:10.1007/s10549-005-9098-3] [PMID]

7. Laudioso D, Muscogiuri G, Barrea L, Savastano S, Colao A. Obesity and breast cancer in premenopausal women: Current evidence and future perspectives. Eur J Obstet Gyn R B. 2018; 230: 217-21. [DOI:10.1016/j.ejogrb.2018.03.050] [PMID]

8. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015;1(8):1145-53. [DOI:10.1001/jamaoncol.2015.2413] [PMID]

9. Safi N, Saunders CH, Haven A, et al. Gestational breast cancer in New South Wales: A population-based linkage study of incidence, management, and outcomes. PloS One. 2021;16(1): e0245493. [DOI:10.1371/journal.pone.0245493] [PMID] [PMCID]

10. Noyes RD, Sphanos JR WJ, Montague ED. Breast cancer in women aged 30 and under. Cancer. 1982;49(6):1302-7. [DOI:10.1002/1097-0142(19820315)49:6.CO;2-0]

11. Anderson BO, Petrek JA, Byrd DR, Senie RT, Borgen PI. Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger. Ann Surg Oncol. 1996;3(2):204-11. [DOI:10.1007/BF02305802] [PMID]

12. Kurtz JM, Jacquemier J, Amalric R, et al. Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol. 1990;8(4):591-8. [DOI:10.1200/JCO.1990.8.4.591] [PMID]

13. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688-97. [DOI:10.1200/JCO.2001.19.6.1688] [PMID]

14. Lamberti M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018; 36(19): 1981-90. [PMCID] [DOI:10.1200/JCO.2018.78.0858] [PMID]

15. Yeo W, Lee HM, Chan A, et al. Risk factors and natural history of breast cancer in younger Chinese women. World J Clin Oncol. 2014;5(5):1097. [PMCID] [DOI:10.5306/wjco.v5.i5.1097] [PMID]

16. Group EBCTC. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-16. [DOI:10.1016/S0140-6736(11)61629-2]

17. Han W, Kang SY. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast cancer Res Treat. 2010;119(1):193. [DOI:10.1007/s10549-009-0388-z] [PMID]

18. Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Seminars in Oncology; 2009; pp 237-249. [PMCID] [PMID] [DOI:10.1053/j.seminoncol.2009.03.001]

19. Shannon C, Smith I. Breast cancer in adolescents and young women. Eur J Cancer 2003;39(18):2632-42. [DOI:10.1016/S0959-8049(03)00669-5]

How to Cite This Article:

Kadkhodaei B, Mosalaei A, Omidvari S, Ansari M, Mohammadianpanah M, Ahmadloo N, et al. Evaluation of the Long-Term Survival in Non-Metastatic Young Breast Cancer Patients in South of Iran. J Adv Med Biomed Res. 2022; 30(141): 333-9.